Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Initiates Coverage on IDEAYA Biosciences with Buy Rating and 55 Price Target

Elaine Mendonca by Elaine Mendonca
March 8, 2024
in Breaking News
0
Biotechnology Markets and money
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

BTIG analyst Justin Zelin has recently started covering IDEAYA Biosciences (NASDAQ: IDYA) and has given it a Buy rating with a Price Target of $55. This optimistic evaluation shows faith in the company’s future prospects. The Buy rating and price target suggest a promising forecast for IDEAYA Biosciences’ stock performance in the market.

IDYA Stock Shows Strong Performance on March 8, 2024 with Positive Price Momentum

On March 8, 2024, IDYA stock showed strong performance, trading near the top of its 52-week range and above its 200-day simple moving average. This indicates positive price momentum for the stock.

IDYA shares opened at $46.27, which was $1.04 higher than its previous close. Throughout the trading day, the stock saw a price increase of $1.09, resulting in a 2.41% rise in its value. This upward movement in price reflects investor confidence and bullish sentiment towards IDYA.

IDYA Stock Sees Significant Decrease in Revenue and Net Income in 2024

On March 8, 2024, IDYA stock experienced a significant decrease in total revenue compared to the previous year and quarter. According to data from CNN Money, the company reported total revenue of $23.39 million for the past year, which represents a 54.08% decrease from the previous year. In the fourth quarter of the same year, IDYA reported total revenue of $3.92 million, marking a 51.19% decrease from the previous quarter.

Similarly, IDYA also reported a decline in net income for the past year and quarter. The company reported a net income of -$112.96 million for the past year, representing a 92.59% decrease from the previous year. In the fourth quarter, IDYA reported a net income of -$33.95 million, which remained unchanged from the previous quarter.

Furthermore, IDYA’s earnings per share (EPS) also saw a decrease compared to the previous year, but remained stable from the previous quarter. The company reported an EPS of -$1.96 for the past year, marking a 38.76% decrease from the previous year. In the fourth quarter, IDYA reported an EPS of -$0.52, which remained unchanged from the previous quarter.

Overall, IDYA stock performance on March 8, 2024, was characterized by declining total revenue and net income compared to the previous year and quarter. Investors may need to closely monitor IDYA’s financial performance and market trends to make informed decisions about their investments in the company.

Tags: IDYA
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Industrial Metals and Mining stock Trading

Analysts Bullish on Gates Industrial Corporation Upgraded Rating and Price Target

Finance_ Trading ratings today (2)

FIGS Shares Decline After Oppenheimer Downgrade

Finance_Investment (2)

Truist Securities Analyst Maintains Hold Rating on Vornado Realty with Revised Price Target

Recommended

Anticipating Navigator Holdings Quarterly Earnings Report Analysts Predict 030 EPS

2 years ago
Sandy Spring Stock

Sandy Spring Bancorp’s Final Chapter: A New Era Under Atlantic Union

3 months ago
Certara Stock

Certara Stock: Regulatory Milestone and Strong Fundamentals Fuel Recovery Hopes

6 months ago
Meta Stock

Meta Faces Mounting Pressure from Regulators and Strategic Shifts

2 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

Tellurian Acquisition Finalized as Woodside Takes Control

Coherus BioSciences Forges Key Oncology Alliance with Janssen

TCG BDC Investors Await Key Financial Milestones

Navigating Change: Schnitzer Steel’s Digital and Structural Evolution

Akso Health Group Pivots to Oncology with Global Patient Initiative

Trending

Deluxe Stock
Analysis

Deluxe Stock Gains Momentum on Successful Fintech Transition

by Kennethcix
February 6, 2026
0

Deluxe Corporation is successfully shedding its legacy identity as a check-printing specialist. The company's strategic pivot toward...

Hydrofarm Holdings Inc Stock

Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches

February 6, 2026
Northeast Bancorp Stock

Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

February 6, 2026
Vir Biotechnology Stock

Vir Biotechnology’s 2026 Pipeline: A Year of Pivotal Clinical Data

February 6, 2026
Tellurian Stock

Tellurian Acquisition Finalized as Woodside Takes Control

February 6, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Deluxe Stock Gains Momentum on Successful Fintech Transition
  • Hydrofarm Holdings: Q4 2025 Earnings Report Date Approaches
  • Northeast Bancorp Reports Robust Loan Growth Amid Strong Quarterly Performance

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com